JF

Jim Faulkner

Non Executive Board Member at Vitarka Therapeutics

London, England

Overview 

Jim Faulkner is an Independent Consultant specializing in Cell and Gene Therapy development and serves as a Non-Executive Director. With a background including roles at GlaxoSmithKline as VP in various departments and as SVP at Autolus Ltd., Faulkner's career highlights include leadership positions in biopharmaceutical development and significant contributions to the advancement of cell and gene therapy technologies. Currently based in London, England, Jim Faulkner's expertise spans across the pharmaceutical industry, with notable roles at organizations such as GlaxoSmithKline, Autolus Ltd., and Cell and Gene Therapy Catapult, showcasing a strong focus on drug development, regulatory affairs, and clinical research within the biotechnology sector.

Work Experience 

  • Independent Consultant

    2023 - Current

  • Non Executive Board Member

    2024

  • Non Executive Board Member

    2024

  • Chief Technical Advisor

    2024 - 2024

  • Chief Technology Officer

    2020 - 2024

Ascidian Therapeutics is a biotechnology company that focuses on medical and clinical gene therapy.

Raised $90,000,000.00 from Apple Tree Partners and Apple Tree Partners.

  • Venture Partner

    2020 - 2023

Apple Tree Partners is a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services.

Raised $5,000,000.00.

  • SVP, Product Delivery

    2015 - 2019

  • VP, CMC and Supply, Rare Disease Unit

    2010 - 2015

  • Vice President, Biopharm Process Research

    2007 - 2010

  • VP, Early Stage Biopharm Development

    2004 - 2007

  • WW Director, Biopharm Analytical Sciences

    2001 - 2004

  • Section Head, Molecular Analysis

    1998 - 2000

  • Team Leader, Biopharmaceutical Analysis

    1993 - 1998

  • Senior Clinical Scientist, Molecular Genetics

    1987 - 1993

  • Research Assistant, Molecular Genetics

    1986 - 1987

Articles About Jim

Relevant Websites